Admissions:
None
Delistings:
None
Potential** Initial Public Offerings:
Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed. A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO. The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. The Company reports the IPO has received strong investor interest and based on firm orders received to date, the institutional offer is heavily oversubscribed. Deal size and timing remains TBC.
Market Movers:
Updated 4 June 2025: Ajax Resources (AJAX.L) is planning to move to the Aquis Stock Exchange Growth Market Access Category from the Main Market of the London Stock Exchange. The Company expects cancellation to take place at 08:00 BST on 18 June 2025, with Admission to trading on AQSE to occur concurrently. Ajax is pursuing a strategy as a natural resources investment company, with a focus on Copper, Gold, Zinc, Uranium, and Lead. The Company completed its first acquisition on 21 May 2025. The Company’s first acquisition was the purchase of Puna Metals S.A., holding the mining rights for 12 licences, collectively forming the Eureka Gold and Copper project in the north-west corner of the Province of Jujuy in Argentina.
13th June: Tap Global Group plc (AQSE:TAP), the digital finance hub that brings money payments and cryptocurrency settlement services together in a single user-friendly app, announced its intention to apply for Admission to trading on AIM and cancel the Admission of its Ordinary Shares to trading on the AQSE Growth Market. Expected Admission will become effective on AIM, at 8.00 a.m. on 27 June 2025. Cancellation of the trading of the Ordinary Shares on the AQSE Growth Market will take place simultaneously with Admission.
Coinsilium Group Limited 15.05p £53.26m (AQSE: COIN)
The investor, advisor, and venture builder provided an update on its Bitcoin treasury activity and that of its wholly owned Gibraltar subsidiary, Forza Gibraltar Limited, established to implement the Company’s dedicated Bitcoin-focused treasury operations. Details of the latest Bitcoin acquisition are as follows: Number of Bitcoin Purchased is 6.5577, Average Purchase Price of £77,770.36 per Bitcoin ($105,572.30 per Bitcoin) with total Purchase Amount of £510,000. Forza’s total Bitcoin holdings stand at 25.2392 Bitcoin with a total value of £1,962,695.09 ($2,662,609.40).
EDX Medical Group 12.25p £45.6m (AQSE: EDX)
The Company which develops digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular disease, and infectious diseases, announces today it has signed a memorandum of understanding with Spire Healthcare Group plc (LSE: SPI). Under the terms of the memorandum of understanding, EDX Medical and Spire Healthcare will explore opportunities to utilise new diagnostic products and patient testing services.
Falcon Oil & Gas Ltd 9.65p £109.4m (FOG.L)
The international oil & gas Company announced that Shenandoah S2-2H ST1 achieved an average 30-day initial production flow rate of 7.2 million cubic feet per day over 1,671 metres (5,483 foot) across a 35 stage stimulated length within the Amungee Member B-Shale in the Beetaloo Sub-basin, Northern Territory, Australia, making it the highest IP30 result in the Beetaloo to date.
The results demonstrate the commercial deliverability of gas from the Amungee Member B-Shale in the Australian East Coast gas market that typically sells at a premium to Henry Hub in the US and under long term CPI-linked contracts.
Ondine Biomedical 10.50p £46.56m (OBI.L)
The Canadian life sciences Company announces that Dr. Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, has been awarded the President's Award at the 19th World Congress of the International Photodynamic Association (IPA) in Shanghai. This prestigious award is one of IPA's highest honours, reserved for individuals whose work is making a transformational impact on healthcare through photodynamic therapy. Dr. Bond was honoured for his pioneering leadership in implementing antimicrobial photodynamic therapy (Ondine's Steriwave photodisinfection) in the UK's National Health Service, a groundbreaking antimicrobial innovation used to prevent surgical site infections.
Physiomics 0.5p £1.5m (PYC.L)*
The mathematical modelling, data science, and biostatistics Company supporting the development of new therapeutics and personalised medicine solutions announced the recruitment of Mr Jesse Thissen as Head of Biometrics, as well as the signing of the Company's first ever two Biometrics contracts.
The two new contracts are with a UK headquartered clinical-stage biopharmaceutical company developing immunotherapies that target a range of diseases. The combined estimated value of both contracts is £111,000. In addition, Mr. Jesse Thissen will be joining the team as Head of Biometrics, effective 1 July 2025. As an experienced biostatistician with a background of working across Large Pharma (AstraZeneca), Biotech, Consumer Health and Contract Research Organisations, Jesse will lead the Company's new Biometrics service-line.
Safestay 23.5p £15.3m (SSTY.L)
One of Europe’s largest hostel groups announced that it has been awarded a business interruption insurance claim totalling £1.4m (net of associated professional fees). The claim relates to the business interruption experienced by the Group during the Covid-19 pandemic. Payment of the claim will be received by the Group within the next 21 days and will be recognised as a post-balance sheet event in Safestay's forthcoming 2024 financial results, which the Group plans to release later this month.
Seeing Machines Limited 2.375p £113.5m (SEE.L)
The advanced computer vision technology Company that designs AI-powered operator monitoring systems to improve transport safety announces that it has signed an agreement to supply additional Guardian Backup-driver Monitoring Systems (BdMS) to a world-leading North American self-driving car company. The agreement, valued at around US$1.2m, will see Guardian BdMS deployed into the autonomous mobility company's test vehicles as they seek to expand across new sites and locations.
Sunda Energy 0.027p £7.8m (SNDA.L)
The AIM-quoted exploration and appraisal Company focused on gas assets in Southeast Asia announces that the planned Chuditch-2 appraisal well on the Chuditch field in the TL-SO-19-16 Production Sharing Contract, planned for drilling by the Company's wholly owned Timor-Leste subsidiary SundaGas in H2 2025, is now expected to be drilled in H1 2026. The delay is due to the absence at the present time of certain essential logistical services in Timor-Leste that are mutually acceptable to the joint venture partners, and that meet the required international operational and safety standards.
The Artisanal Spirits Company 50.0p £35.4m (ART.L)
The owner of The Scotch Malt Whisky Society (SMWS), the curator and provider of premium single cask Scotch malt whisky and other spirits for sale primarily online to a discerning global membership, announced the successful launch of a new franchise in Vietnam. The launch of the franchise allows SMWS to serve members in one of the world's top 10 markets for Ultra-Premium Scotch Whisky, based on value, with an estimated total addressable market of $239m (source: IWSR 2024). It marks another milestone in the Group's strategic expansion in Asia, complementing the more recent 2023 franchise launches in Korea and subsidiary in Taiwan respectively, alongside the longer established China and Japan subsidiaries.
The Mission Group 28.5p £25.5m (TMG.L)
The Brand Performance Group, comprising of digital marketing and specialist communications Agencies, updates in an AGM trading statement to 16 June 2025. Despite macro-economic uncertainty, the Group has remained focused on maintaining operating income and margin with full year performance expected to be second half weighted. Client retention has remained strong and new wins including Google, TikTok International, Bata, and the Federal Reserve Bank of Chicago. The restructuring of operations to become more agile and decentralised is progressing with an AI strategy and a new Chief Transformation Director appointed. The search for a new CEO continues and an update is anticipated in H2.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
